| abstract |
Oligomers are provided that are capable of reducing the CD28 gene in T-cells. In addition to the specific sequence, the invention encompasses a class of oligomers having at least two sequences of GGGG separated by 3-5 bases. The aim is to include the CD28 gene, the 5 'untranslated portion and the initiation codon, and their respective transcripts. The method includes administering to the subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof for the treatment and / or prophylaxis of graft versus host disease, plaque-like shock syndrome, viral disease, psoriasis, type I (insulin-dependent diabetes mellitus), thyroiditis, sarcoidosis, multiple sclerosis, autoimmune uveitis, rheumatoid arthritis, And the use of oligomers to modulate the immune system's immune system's immune response in an immune system mediated disease, including inflammatory bowel disease. |